Extracorporeal cell therapy of septic shock patients with donor granulocytes: a pilot study

Table 1 Patients characteristics, illness severity, premorbidity and clinical outcome for study cohort (n = 10).

Patient	Major diagnoses at inclusion	Premorbidity	APACHE II at ICU arrival	SOFA at ICU arrival/at inclusion	SAPS II at ICU arrival/at inclusion	Hospital survival	Inclusion at ICU day	Time between inclusion and first treatment in days
1	Pneumonia, ALI, SS	Alcohol abuse	37	15/16	96/80	Survived	1	2
2	Necrotizing pancreatitis, Pneumonia, SS	Alcohol abuse	27	12/11	61/61	Survived	9	1
3	Pneumonia, ALI, Urogenital infection, SS	Ischemic heart disease, Hydrocephalus, brain-tumor operation	30	12/11	66/58	Died (Day 18)	3	1
4	ALI, SS, Liver failure	Liver cirrhosis, COPD, Diabetes mellitus	37	17/17	72/73	Died (Day 9)	10	1
5	Cardiopulmonary resuscitation, ALI, SS	Alcohol abuse, Encephalopathy, Ischemic heart disease	36	11/13	83/66	Survived	4	1
6	Mediastinitis, SS	Alcohol abuse	27	14/13	70/63	Survived	1	2
7	Hip joint endoprosthesis infection, SS	Diabetes mellitus	21	8/6	35/35	Died (Day 40)	1	3
8	Postoperative shock after ACB-surgery, ARF, SS	Ischemic heart disease, Cardiac failure	38	13/9	74/50	Survived	6	12
9	Renal failure, Kidney infection, SS	Polycystic Kidney and Liver	29	8/12	72/31	Survived	3	2
10	Thoracic infection after sternum resection, ARF, SS	Radio-Necrosis of Sternum after Radio-Chemotherapy due to Breast Cancer	17	8/11	33/70	Died (Day 6)	27	3
Median			29	12/11	70/61		4	2
Mean			29.9	11.8/11.9	66.2/58.7		6.5	2.8

ACB, aortocoronary bypass, ALI, acute lung injury, ARF, acute renal failure, COPD, chronic obstructive pulmonary disease, SS, septic shock

ISSN: 1364-8535